Market Research Logo

EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2025

EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2025

Summary

Cystic Fibrosis (CF) is an inherited disorder that affects the cells that produce mucus, sweat and digestive juices, and also causes severe damage to the lungs, digestive system and other organs. These secreted fluids are normally thin and slippery. But in people with CF, a defective gene, known as the CFTR gene, causes the secretions to become sticky and thick. Instead of acting as a lubricant, the secretions plug up tubes, ducts and passageways (Mayo Clinic, 2016). In the lungs, the mucus clogs the airways and traps bacteria leading to infections, extensive lung damage and eventually, respiratory failure.

Key differences in the CF epidemiology between countries are influenced by genotype mutations, national screenings, and surveillance systems through national registries. The UK has the greatest prevalence proportion of CF, which may be the result of a strong presence of the mutations in the country (UK CFR, 2014). Reports indicate that British and French ancestries are the origins of CF-causing mutations (Physicians Committee for Responsible Medicine, 2008). National CF screenings are also imperative in detecting and capturing the true CF prevalence of a country.

According to the forecast adjusted for underestimation of registry data, the diagnosed incident cases of CF in the 7MM will decrease from 2,217 cases in 2015 to 2,074 cases in 2025, at an AGR of negative 0.64%. The US will have the highest number of diagnosed incident cases of CF among the 7MM throughout the forecast period, while Germany will have the lowest.

In the 7MM, based on registry data, our epidemiologists forecast that the diagnosed prevalent cases of CF will increase from 63,571 cases in 2015 to 73,368 cases in 2025, at an AGR of 1.54%. The US will have the highest number of diagnosed prevalent cases of CF among the 7MM throughout the forecast period, while Spain will have the lowest.

The report EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2025 provides an overview of the risk factors, comorbidities, and the global and historical trends for CF in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Canada). It includes a 10-year epidemiological forecast for the diagnosed incident cases of CF, diagnosed prevalent cases of CF, and CF mortality based on county-specific registry data. Moreover this report provides the in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Scope

  • The Cystic Fibrosis (CF) EpiCast Report provides an overview of the risk factors and global trends of CF in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Canada). It includes a 10-year epidemiology forecast of diagnosed incident cases of CF, diagnosed prevalent cases of CF, and CF mortality segmented by sex in these seven markets. Diagnosed prevalent cases of CF are further segmented by age (starting from zero years of age and up to 85 years and older), specific mutation type, and chronic Methicillin-resistant Staphylococcus aureus (MRSA) infection.
  • The CF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The CF EpiCast series will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global CF market.
  • Quantify patient populations in the global CF market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CF therapeutics in each of the markets covered.
  • Identify the percentage of CF diagnosed prevalent cases by age, sex, specific mutation type, and MRSA infection.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 Related Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global Trends
3.3.1 Diagnosed Incidence and Diagnosed Prevalence
3.4 Forecast Methodology
3.4.1 Sources Used
3.4.2 Forecast Assumptions and Methods
3.4.3 Sources Not Used
3.5 Epidemiological Forecast for CF (2015-2025)
3.5.1 Diagnosed Incident Cases, Based on Registry Data
3.5.2 Diagnosed Prevalent Cases, Based on Registry Data
3.5.3 CF Mortality, Based on Registry Data
3.5.4 Diagnosed Incident Cases, Adjusted for Underestimation
3.5.5 Diagnosed Prevalent Cases, Adjusted for Underestimation
3.5.6 CF Mortality, Adjusted for Underestimation
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 Physicians and Specialists Included in this Study
4.3 High-Prescribing Physician Survey
4.4 About the Authors
4.4.1 Epidemiologist
4.4.2 Reviewers
4.4.3 Global Director of Therapy Analysis and Epidemiology
4.4.4 Global Head of Healthcare
4.5 About GlobalData
4.6 About EpiCast
4.7 Contact Us
4.8 Disclaimer
1.1 List of Tables
Table 1: Risk Factors and Comorbidities of CF
Table 2: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of CF (Based on Registry Data)
Table 3: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of CF (Based on Registry Data)
Table 4: 7MM, Sources Used for Segmentation of Diagnosed Prevalent Cases of CF by Specific Mutations (Based on Registry Data)
Table 5: 7MM, Sources Used to Forecast the Proportion of Diagnosed Prevalent Cases of CF by Chronic MRSA Infection (Based on Registry Data)
Table 6: 7MM, Sources Used to Forecast CF Deaths (Based on Registry Data)
Table 7: 7MM, Proportion of CF Cases Reported to Respective CF Registries (Primary Research)
Table 8: 7MM, Sources Not Used in the Epidemiological Analysis of CF
Table 9: 7MM, Diagnosed Incident Cases of CF, All Ages, Both Sexes, N, Selected Years 2015-2025 (Based on Registry Data)
Table 10: 7MM, Sex-Specific Diagnosed Incident Cases of CF, All Ages, N (Row %), 2015 (Based on Registry Data)
Table 11: 7MM, Diagnosed Prevalent Cases of CF, All Ages, Both Sexes, N, Selected Years 2015-2025 (Based on Registry Data)
Table 12: 7MM, Age-Specific Diagnosed Prevalent Cases of CF, Both Sexes, N (Row %), 2015 (Based on Registry Data)
Table 13: 7MM, Sex-Specific Diagnosed Prevalent Cases of CF, All Ages, N (Row %), 2015 (Based on Registry Data)
Table 14: 7MM, Diagnosed Prevalent Cases of CF with Chronic MRSA Infection, All Ages, Both Sexes, N, Selected Years 2015-2025 (Based on Registry Data)
Table 15: 7MM, CF Deaths, All Ages, Both Sexes, N, Selected Years 2015-2025 (Based on Registry Data)
Table 16: 7MM, Sex-Specific CF Deaths, All Ages, N (Row %), 2015 (Based on Registry Data)
Table 17: 7MM, Diagnosed Incident Cases of CF, All Ages, Both Sexes, N, Selected Years 2015-2025 (Adjusted for Underestimation)
Table 18: 7MM, Sex-Specific Diagnosed Incident Cases of CF, All Ages, N (Row %), 2015 (Adjusted for Underestimation)
Table 19: 7MM, Diagnosed Prevalent Cases of CF, All Ages, Both Sexes, N, Selected Years 2015-2025 (Adjusted for Underestimation)
Table 20: 7MM, Age-Specific Diagnosed Prevalent Cases of CF, Both Sexes, N (Row %), 2015 (Adjusted for Underestimation)
Table 21: 7MM, Sex-Specific Diagnosed Prevalent Cases of CF, All Ages, N (Row %), 2015 (Adjusted for Underestimation)
Table 22: 7MM, Diagnosed Prevalent Cases of CF with Chronic MRSA Infection, All Ages, Both Sexes, N, Selected Years 2015-2025 (Adjusted for Underestimation)
Table 23: 7MM, CF Deaths, All Ages, Both Sexes, N, Selected Years 2015-2025 (Adjusted for Underestimation)
Table 24: 7MM, Sex-Specific CF Deaths, All Ages, N (Row %), 2015 (Adjusted for Underestimation)
Table 25: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2016
1.2 List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of CF, All Ages, Both Sexes, N, 2015 and 2025 (Forecast Based on Registry Data)
Figure 2: 7MM, Diagnosed Prevalent Cases of CF, All Ages, Both Sexes, N, 2015 and 2025 (Forecast Based on Registry Data)
Figure 3: 7MM, CF Deaths, All Ages, Both Sexes, N, 2015 and 2025 (Forecast Based on Registry Data)
Figure 4: 7MM, Diagnosed Incident Cases of CF, All Ages, Both Sexes, N, 2015 and 2025 (Forecast Adjusted for Underestimation)
Figure 5: 7MM, Diagnosed Prevalent Cases of CF, All Ages, Both Sexes, N, 2015 and 2025 (Forecast Adjusted for Underestimation)
Figure 6: 7MM, CF Deaths, All Ages, Both Sexes, N, 2015 and 2025 (Forecast Adjusted for Underestimation)
Figure 7: 7MM, Diagnosed Incident Cases of CF, All Ages, Both Sexes, N, 2015-2025 (Based on Registry Data)
Figure 8: 7MM, Sex-Specific Diagnosed Incident Cases of CF, All Ages, N, 2015 (Based on Registry Data)
Figure 9: 7MM, Diagnosed Prevalent Cases of CF, All Ages, Both Sexes, N, Selected Years 2015-2025 (Based on Registry Data)
Figure 10: 7MM, Age-Specific Diagnosed Prevalent Cases of CF, Both Sexes, N, 2015 (Based on Registry Data)
Figure 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of CF, All Ages, N, 2015 (Based on Registry Data)
Figure 12: 7MM, Age-Standardized Diagnosed Prevalence of CF, All Ages, N, 2015 (Based on Registry Data)
Figure 13: 7MM, Diagnosed Prevalent Cases of CF with Specific Mutations, Both Sexes, All Ages, N, 2015 (Based on Registry Data)
Figure 14: 7MM, Diagnosed Prevalent Cases of CF with Chronic MRSA Infection, Both Sexes, All Ages, N, 2015 (Based on Registry Data)
Figure 15: 7MM, CF Deaths, All Ages, Both Sexes, N, Selected Years 2015-2025 (Based on Registry Data)
Figure 16: 7MM, Sex-Specific CF Deaths, All Ages, N, 2015 (Based on Registry Data)
Figure 17: 7MM, Diagnosed Incident Cases of CF, All Ages, Both Sexes, N, 2015-2025 (Adjusted for Underestimation)
Figure 18: 7MM, Sex-Specific Diagnosed Incident Cases of CF, All Ages, N, 2015 (Adjusted for Underestimation)
Figure 19: 7MM, Diagnosed Prevalent Cases of CF, All Ages, Both Sexes, N, Selected Years 2015-2025 (Adjusted for Underestimation)
Figure 20: 7MM, Age-Specific Diagnosed Prevalent Cases of CF, Both Sexes, N, 2015 (Adjusted for Underestimation)
Figure 21: 7MM, Sex-Specific Diagnosed Prevalent Cases of CF, All Ages, N, 2015 (Adjusted for Underestimation)
Figure 22: 7MM, Diagnosed Prevalent Cases of CF with Specific Mutations, Both Sexes, All Ages, N, 2015 (Adjusted for Underestimation)
Figure 23: 7MM, Diagnosed Prevalent Cases of CF with Chronic MRSA Infection, Both Sexes, All Ages, N, 2015 (Adjusted for Underestimation)
Figure 24: 7MM, CF Deaths, All Ages, Both Sexes, N, Selected Years 2015-2025 (Adjusted for Underestimation)
Figure 25: 7MM, Sex-Specific CF Deaths, All Ages, N, 2015 (Adjusted for Underestimation)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report